Stromal COL11A1: Mechanisms of Stroma-Driven Multidrug Resistance in Breast Cancer and Biomarker Potential
Andreea Onofrei (Popa), Felicia Mihailuta, Daniela Mihalache, Cristina Chelmu Vodă, Sanda Jurja, Sorin Deacu, Mihaela Cezarina Mehedinți, Randolph C Elble · 2025
Read Stromal COL11A1: Mechanisms of Stroma-Driven Multidrug Resistance in Breast Cancer and Biomarker Potential by Andreea Onofrei (Popa), Felicia Mihailuta, Daniela Mihalache, Cristina Chelmu Vodă, Sanda Jurja, Sorin Deacu, Mihaela Cezarina Mehedinți, Randolph C Elble (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731117.txt.
Description
Andreea Onofrei and co-authors review stromal COL11A1, a collagen made by cancer-associated fibroblasts, as a driver of drug resistance in breast cancer. Resistance is a cause of treatment failure, above all in estrogen receptor-positive tumors that first respond to hormone therapy, then stop. COL11A1 is a minor fibrillar collagen, but it keeps turning up where tumors progress and prognosis is poor.
The review gathers work from 2011 to 2025, in breast cancer and in ovarian, pancreatic, and lung cancers. Across cancers, high COL11A1 tracks with a remodeled stroma, with cells shifting to a mobile state, and with resistance to both hormone drugs and chemotherapy. In breast cancer it may also shape the immune surroundings of the tumor, and it holds promise as a prognostic marker. Most proof is retrospective or preclinical, and clinical validation is thin.
Catalog record
| CREATOR | Andreea Onofrei (Popa), Felicia Mihailuta, Daniela Mihalache, Cristina Chelmu Vodă, Sanda Jurja, Sorin Deacu, Mihaela Cezarina Mehedinți, Randolph C Elble |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |